Literature DB >> 11745219

MUC1, MUC2, MUC5AC, and MUC6 expressions in gastric carcinomas: their roles as prognostic indicators.

H S Lee1, H K Lee, H S Kim, H K Yang, Y I Kim, W H Kim.   

Abstract

BACKGROUND: Although mucin expressions appear to be correlated with prognoses in patients with various cancers, several studies have reported conflicting and inconclusive results on the prognostic significance of mucin expression in gastric carcinomas.
METHODS: To clarify the correlations between clinicopathologic profiles and the patients' survival, the expression of MUC1, MUC2, MUC5AC, MUC6 mucins and the p53 protein were evaluated immunohistochemically in 300 consecutive gastric carcinomas using the tissue-array method. In addition, 59 gastric adenomas and 57 adenoma-associated carcinomas were investigated.
RESULTS: MUC1 was expressed in 2 (3.4%) cases of gastric adenoma, and MUC2 in 19 (32.2%) cases of gastric adenoma, out of a total of 59 lesions. In consecutive gastric carcinomas, 24.3% of gastric carcinomas expressed MUC1, 27.3% expressed MUC2, 38.0% expressed MUC5AC and 12.7% expressed MUC6. The rate of MUC1 expression in gastric carcinomas was significantly higher than in associated gastric adenomas (P < 0.01). The patients with MUC1-positive carcinomas showed significantly poorer survival than those with MUC1-negative carcinomas. On the other hand, MUC2, MUC5AC and MUC6 expressions were not significantly associated with patient survival. Interestingly, combined evaluation revealed that the group with the MUC1-negative plus p53-negative expression pattern showed a better prognosis than the remaining cases. In contrast, the group with the MUC2-negative plus p53-positive pattern showed a worse prognosis.
CONCLUSIONS: Mucin expression is altered in gastric adenoma and carcinoma, and MUC1 mucin expression is significantly associated with poorer outcome in gastric carcinomas. A MUC1-negative plus p53-negative pattern or a MUC2-negative plus p53-positive pattern may predict outcome in patients with gastric carcinomas. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745219     DOI: 10.1002/1097-0142(20010915)92:6<1427::aid-cncr1466>3.0.co;2-l

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  65 in total

1.  Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes.

Authors:  In Sil Choi; Hye Seung Lee; Keun-Wook Lee; Haeryoung Kim; Ki Hwan Kim; Yu Jung Kim; Jee Hyun Kim; Woo Ho Kim; Jong Seok Lee
Journal:  Med Oncol       Date:  2010-06-09       Impact factor: 3.064

Review 2.  Prognostic value of Muc5AC in gastric cancer: A meta-analysis.

Authors:  Chuan-Tao Zhang; Ke-Cheng He; Fei Pan; Yuan Li; Jiang Wu
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

3.  Evaluation of mucin expression patterns in gastric borderline (group III) lesions.

Authors:  Hideki Minematsu; Yasuharu Saito; Rie Kakinoki; Akira Andoh; Ryoji Kushima; Yoshihide Fujiyama
Journal:  J Gastroenterol       Date:  2006-06       Impact factor: 7.527

4.  Phenotype analysis by MUC2, MUC5AC, MUC6, and CD10 expression in Epstein-Barr virus-associated gastric carcinoma.

Authors:  Rita Rani Barua; Hiroshi Uozaki; Ja-Mun Chong; Tetsuo Ushiku; Rumi Hino; Moon-Sung Chang; Hideo Nagai; Masashi Fukayama
Journal:  J Gastroenterol       Date:  2006-08       Impact factor: 7.527

5.  Predicting individual survival after gastric cancer resection: validation of a U.S.-derived nomogram at a single high-volume center in Europe.

Authors:  Alexander R Novotny; Christoph Schuhmacher; Raymonde Busch; Michael W Kattan; Murray F Brennan; Jörg Rüdiger Siewert
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

6.  The differences between the localizations of MUC1, MUC5AC, MUC6 and osteopontin in quail proventriculus and gizzard may be a reflection of functional differences of stomach parts.

Authors:  Narin Liman; Emel Alan; Güner Küçük Bayram
Journal:  J Anat       Date:  2010-05-11       Impact factor: 2.610

7.  The contribution of cell phenotype to the behavior of gastric cancer.

Authors:  Enrico Solcia; Catherine Klersy; Alessandro Vanoli; Federica Grillo; Rachele Manca; Francesca Tava; Ombretta Luinetti; Roberto Fiocca
Journal:  Gastric Cancer       Date:  2013-01-18       Impact factor: 7.370

8.  Loss of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in gastric cancers.

Authors:  Hye Seung Lee; Han-Kwang Yang; Woo Ho Kim; Gheeyoung Choe
Journal:  Cancer Res Treat       Date:  2005-04-30       Impact factor: 4.679

9.  Expression of Cdx2 and the phenotype of advanced gastric cancers: relationship with prognosis.

Authors:  Tsutomu Mizoshita; Tetsuya Tsukamoto; Hayao Nakanishi; Ken-ichi Inada; Naotaka Ogasawara; Takashi Joh; Makoto Itoh; Yoshitaka Yamamura; Masae Tatematsu
Journal:  J Cancer Res Clin Oncol       Date:  2003-10-14       Impact factor: 4.553

10.  Prognostic significance of loss of c-fos protein in gastric carcinoma.

Authors:  Seon Pil Jin; Ji Hun Kim; Min A Kim; Han-Kwang Yang; Hee Eun Lee; Hye Seung Lee; Woo Ho Kim
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.